MULTI-DRUG APPROACHES TO NASH: WHAT’S IN THE DEVELOPMENT PIPELINE?

Michael Johnston1, Janisha Patel1, Christopher D Byrne2,3.
1 Department of Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. ORCID: 0000-0002-4704-8349 (MPJ); 0000-0002-4634-0751 (JP).
2 Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. ORCID
3 National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, UK. ORCID: 0000-0001-6322-7753 (CDB).

1. INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) was first described over 40 years ago.1 In subsequent years it has become clear that obesity is an important risk factor for NAFLD2, and that NAFLD increases the risk of type 2 diabetes (T2DM) and cardiovascular disease (CVD)3.

With the ‘rising tide’ of obesity, the prevalence of NAFLD has recently been estimated to affect up to a quarter of the global adult population.4 With such a high prevalence of NAFLD, the numbers of patients with more severe liver disease, i.e. non-alcoholic steatohepatitis (NASH), in whom progression to advanced fibrosis, cirrhosis, decompensated liver disease, or hepatocellular carcinoma may occur, has increased markedly. This burden of disease is also markedly increasing the numbers of NASH liver transplant registrants5 with important implications for the provision of health care services.

To date, the existing evidence shows that two drugs (pioglitazone and liraglutide) that are licensed for the treatment of T2DM, and that principally act in adipose tissue, may benefit a proportion of patients with NASH. Although these drugs do not improve NASH in all patients, notably, treatment with both drugs confers benefits beyond the liver in treating T2DM and reducing risk of CVD.6,7

Thus, for new drugs in the NASH-treatment pipeline, given the increased extra-hepatic morbidity and mortality associated with NAFLD, it is now important that any benefits (or harms) beyond the liver are described. We consider that the paradigm for the ideal drug in NASH would be an agent that not only ameliorated NASH but also benefitted T2DM and CVD (see Figure 1). In this commentary, we describe a number of promising new pharmacological agents identified from pre-clinical models and early phase trials that may benefit NASH (summarized in Table 1). In Table 1 we also describe the potential benefits (and harms) of these drugs for T2DM and CVD.

2. DRUGS IN DEVELOPMENT FOR THE TREATMENT OF NASH

We have chosen to divide the drugs that benefit NASH according to whether their principle mode of action is on steatosis, or steatohepatitis and fibrosis.

2.1 STEATOSIS

Fatty infiltration of the liver (hepatic steatosis), may be isolated or progress to an inflammatory process of hepatocyte ballooning and lobular inflammation. Manipulation of fatty acid metabolism
through an array of mechanisms is a promising strategy for abating this pathological process. Although incompletely understood, targeting bile acid synthesis is one approach that directly influences cholesterol metabolism and benefits NASH. NGM-282 is an analogue of fibroblast growth factor 19 (FGF-19) which has been studied in a phase II trial of patients with a histological diagnosis of NASH. Patients who received NGM-282 achieved 58% and 67% relative reduction in liver fat at 12 weeks at low and high doses respectively. In addition to its effect on steatosis, NGM-282 significantly improved fibrosis score by ≥1 point, without worsened liver fibrosis.

FGF-19 regulates bile acid synthesis, glycogen synthesis and gluconeogenesis as well as affecting a reduction in adipose tissue. FGF-19 has an integral role in the downregulation of bile acid synthesis through inhibition of cholesterol 7a-hydroxylase. However, there are side effects of treatment, potentially limiting the usefulness of FGF-19 treatment. Firstly, diarrhoea was a side-effect of FGF-19. Diarrhoea was managed by ‘separating the timing of injection around meals and decreasing meal size’, and one might speculate that this side-effect resulted in weight loss and thereby decreased liver fat content. Secondly, the increase in serum low-density lipoprotein cholesterol (LDL-C) caused by FGF-19 is undesirable in a patient group in whom cardiovascular risk reduction is of paramount importance. The increase in LDL-C concentration was reduced by treatment with the HMG-CoA reductase inhibitor rosuvastatin. However, we would be cautious about inferring that statins negate all of the adverse effect of NGM-282 on cardiovascular risk, since it is well accepted that treatment of increased LDL-C concentrations with statins does not attenuate all of the increased CVD risk in patients with increased LDL-C concentrations.

A beneficial effect on hepatic fat content has also been demonstrated by another member of the FGF family, FGF-21. Pegbelfermin (BMS-986036) is a pegylated subcutaneous recombinant analogue of FGF-21 which, in a phase II study of 75 overweight/obese patients, showed a significant decrease in hepatic fat fraction compared to placebo over 16 weeks. There was no significant weight change in both placebo and intervention arms of the study. There was a trend towards improvement in LDL-C and high-density lipoprotein cholesterol (HDL-C) concentrations, which although not statistically significant, was consistent with a previous proof-of-concept study demonstrating favourable metabolic effects with treatment.

Hepatic thyroid hormone receptor beta (THR-β) is a novel target for reducing lipotoxic fatty acids in the steatotic hepatocyte. Findings from a phase II study in patients with NAFLD treated with the THR-β agonist VK2809 were presented at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2019. This study demonstrated a median relative reduction in liver fat of >50% compared to 9.4% by placebo. A phase II multi-centre randomised double-blind placebo-controlled trial of patients with biopsy-proven NASH assessed the effect of a similar agent THR-β agonist MGL-3196. The findings were presented at the EASL ILC 2018. MGL-3196 reduced hepatic fat content compared to placebo (AR -7.6% vs -1.6%). These two encouraging studies herald THR-β agonism as a potential therapeutic mechanism for treating NAFLD. We cautiously await more complete peer reviewed reporting of the results of these studies, including data on any adverse events, particularly on the metabolic profile, given animal data has previously demonstrated impaired insulin sensitivity.

Increased de novo lipogenesis (DNL) may contribute to dysregulated fatty acid biosynthesis leading to NAFLD/NASH. GS-0976 is an inhibitor of acetyl-coenzyme A carboxylase (ACC), the rate limiting enzyme in fatty acid synthesis. In a phase II placebo-controlled trial, GS-0976 achieved the primary outcome of >30% reduction in hepatic fat content measured by quantification of magnetic
2.2 STEATOHEPATITIS & FIBROSIS

There are a number of promising agents which ameliorate the inflammatory component of NASH. The peroxisome proliferator-activated receptor (PPAR)-α and –δ agonist Elafibranor is one such agent. Although Elafibranor treatment did not meet the primary endpoint of improvement in NAFLD Activity Score (NAS) without worsening of fibrosis, it did produce a significant improvement in reduction of higher NAS compared to placebo, in post hoc analysis. Furthermore there were significant decreases in LDL-C, triglycerides and HbA1c concentrations. We eagerly await the outcome of the currently registered trial assessing relative effect of Elafibranor on saturated fatty acids in the liver measured by MR spectroscopy (NCT03953456).

For many of the therapeutic agents studied in NASH the anti-inflammatory and anti-fibrotic mechanisms are inextricably linked. Their combined improvement is the primary endpoint in many relevant drug trials. Down-regulation of migration and infiltration of monocytes, macrophages and collagen-promoting hepatic stellate cells formed the basis of the theory behind the rationale for the CENTAUR trial. Antagonism of the CC chemokine receptor types 2 and 5 (CCR2/CCR5) by Cenicriviroc targeted anti-inflammatory and anti-fibrotic mechanisms thought to be beneficial in the amelioration of NASH. CENTAUR was a randomized placebo-controlled trial of 289 patients with NASH who had a NAS ≥ 4 and liver fibrosis stages 1-3. The primary outcome was a ≥ 2 point improvement in NAS with no worsening of fibrosis at one year. Disappointingly there was not a significant difference in primary outcome between the study drug Cenicriviroc and placebo (16% vs 19%). However, the secondary outcome of fibrosis improvement alone attributable to Cenicriviroc was met (20% of patients benefitting in the treatment arm vs 10% in the placebo arm).

Furthermore, no improvement in the metabolic profile was seen in the intervention arm, despite the theory that decreasing macrophage recruitment into adipose tissue via CCR2 antagonism, could benefit insulin resistance. There is an active phase II trial of Cenicriviroc as combination therapy with the FXR agonist Tropifexor in patients with NASH and F2/F3 fibrosis (NCT03517540).

Inhibiting apoptosis signal-regulating kinase 1 (ASK-1) with Selonsertib was the subject of a phase II trial assessing the antifibrotic effect of this treatment in patients with NASH and stage 2-3 liver fibrosis. Selonsertib was administered alone and in combination with the lysl oxidase-like molecule 2 (LOXL-2) monoclonal antibody Simtuzumab. 43% of patients on high dose Selonsertib had ≥1 fibrosis stage reduction, compared to 20% of patients in the Simtuzumab alone group. These improvements in fibrosis correlated with liver stiffness reduction on magnetic resonance elastography (MRE). In the absence of a control group, these results need to be verified in further placebo-controlled trials. We have mentioned above that there is an active trial of Selonsertib in combination therapy, although this trial is not yet recruiting (NCT03449446).

The Caspase-inhibitor Emricasan targets apoptosis and has potential anti-inflammatory effects. A phase II trial which randomised 19 patients with NAFLD to both Emricasan and placebo showed improvement in serum ALT and surrogate biomarkers of apoptosis. However, the complete results
from the larger trials with Emtricitabine are pending. ENCORE-PH enrolled patients with NASH and hepatic venous pressure gradient (HVPG) > 12mmHg (NCT02960204) and ENCORE-NF enrolled patients with biopsy proven NASH and F1-F3 (NCT02686762). Unfortunately, a recent press release announced failure of the intervention to meet the primary endpoint of ≥1 fibrosis stage improvement without worsening of steatohepatitis.23

Finally, with regard to improvement in fibrosis stage without worsening in NASH, it is important to discuss obeticholic acid (OCA).24 FLINT25 was a multi-centre, double-blind, randomised, placebo-controlled phase 2 trial of OCA in patients with biopsy-proven NASH. The primary outcome in FLINT was improvement in NAS without worsening in fibrosis. This was based on liver histological examination after 72 weeks of treatment with either OCA or placebo. FLINT demonstrated that patients treated with OCA achieved the primary outcome in 50/110 patients (50%) compared to placebo which achieved the primary outcome in 23/109 (21%) of patients. This extremely promising result was however tempered by an increase in the side-effect of pruritus, which occurred in 23% of patients in the OCA arm and 6% of patients in the placebo arm. FLINT also showed that OCA treatment produced a marked increase in LDL-C concentration. Despite lipid-lowering therapy an increase in LDL-C concentration persisted at 72 weeks in the OCA group compared to the placebo group.

Following on from the FLINT trial, REGENERATE is a phase 3, multi-centre, randomized, placebo-controlled trial testing the effects of OCA in NASH. The 18 month interim analysis was presented at EASL ILC 201924. The results (presented at EASL ILC 2019) demonstrated that REGENERATE is currently meeting the primary outcome of improvement in fibrosis score by ≥1 stage with no worsening in NASH. (However, it should also be noted that the previously shown improvement in NAS was not demonstrated). Deterioration in lipid profile was also observed in a dose-dependent manner. Pruritus was the most common adverse event (19% placebo, 28% OCA 10mg, 51% OA 25mg). Nonetheless, it is possible that OCA will be the first therapeutic agent to be approved for treatment of NASH with fibrosis, based on these interim analysis results.

3. FUTURE STRATEGIES: COMBINATION THERAPY

It is noteworthy that to date, none of the agents that have shown efficacy in randomized placebo-controlled trials in NASH, have benefitted all of the treated patients. In trying to understand the explanation(s) for this observation, in contrast to trials testing agents for CVD prevention, trials in NASH have been undertaken with small numbers of participants. Consequently, post-hoc sub-group analyses have provided little extra insight into whether specific groups of participants benefit (or not). That said, it is highly likely that the reason for beneficial treatment effects, (or for the failure of treatment efficacy) reflects the complex and varied pathogenesis of liver disease within the spectrum of conditions encapsulated by NAFLD. Put simply, the drivers of disease development and progression in NASH are likely to vary between patients. For example, the pathogenesis of NASH in a normal weight, 40-year-old man who has the patatin-like phospholipase domain-containing protein 3 (PNPLA3) 148 GG genotype, is likely to be very different from the pathogenesis of NASH in an obese, 60 year old women, with type 2 diabetes with no genotypic predisposition to developing NASH. Since the pathogenesis of NASH is influenced by extra-hepatic organs, (e.g. adipose tissue and the intestine), it will also be important to consider the relative influence of treatments in these organs too. Consequently, and analogous to the treatment of hypertension, it is likely that effective
treatments for NASH, will initially involve trials of combination therapies. Having identified combinations of treatments with proven efficacy, these will need to be tailored to individual patients’ requirements, according to their phenotypic and genotypic characteristics.

In Table 2 we have summarized registered trials of combination therapy that are either being planned or are actively recruiting. Although to date, only pioglitazone therapy and vitamin E treatment are two agents with proven efficacy in NASH (recommended for consideration of treatment of NASH by international guidelines), perhaps because these agents are inexpensive, generically available drugs, it is important to note (see Table 2) that there are few combination therapy trials sponsored by Industry, that are utilizing either of these drugs. Although licensed for the treatment of type 2 diabetes, pioglitazone has recently been recommended by three separate international Guidelines for the treatment of NASH.\textsuperscript{26–28} Pioglitazone is also the only recommended NASH drug that targets both adipose tissue metabolism and inflammation, acting through the transcription factor peroxisome proliferator activated receptor gamma (PPAR-γ). However, pioglitazone is known to work in only \textasciicircum 50\% of patients (regardless of diabetes status)\textsuperscript{29–32} and weight gain is a noted side-effect. Therefore, combining pioglitazone with an agent that would counter the weight gain may be a useful therapeutic strategy for combination therapy. Pioglitazone has also been shown to confer additional benefits to treat T2DM and decrease risk of myocardial infarction and stroke.\textsuperscript{33,34} Previous concerns that pioglitazone may increase risk of heart failure may have been overstated and the results of the recent Insulin Resistance Intervention after Stroke (IRIS) trial show that the lower dose of pioglitazone (i.e. 30mg/day) is not associated with any increased risk of heart failure.\textsuperscript{35} Liraglutide is a GLP-1 agonist which facilitates weight loss and that has also been shown to provide benefit in NASH.\textsuperscript{36} Consequently, combination therapy with pioglitazone and liraglutide would seem to be a sensible combination therapy that is not currently being tested in NASH.

4. CONCLUSION

We have described a selection of agents for NAFLD in early phase trials which show favourable effects on hepatic steatosis, steatohepatitis or fibrosis. Whereas we acknowledge that any future decision on accelerated approval of these drugs for NAFLD is currently based upon improvements in liver fibrosis and/or steatohepatitis, we want to draw particular attention to the cardiometabolic effects of these newer agents. There is considerable heterogeneity of the patient phenotype in subjects with NASH, and it will be important not to treat NASH with a new agent that increases CVD risk. Patients with NASH have varying profiles of risk for both hepatic and extrahepatic diseases, such as T2DM and CVD. Eventually treatment of NAFLD may become tailored and based on more accurate and nuanced risk prediction for both liver disease and closely associated extra-hepatic conditions. Given that it is now accepted that the risk of dying from CVD is at least as great, if not greater, than dying from liver-related mortality, treatments that both target the liver and the common extrahepatic diseases are highly attractive potential treatment strategies for NASH. In that sense, there is already good evidence that treatment with pioglitazone in carefully selected patients (who are not at risk of fracture or cardiac failure) fulfills many of these criteria. We consider that future trials of new agents for NASH needs to very carefully assess their impact beyond the liver and on cardiometabolic risk factors and extra-hepatic diseases such as T2DM and CVD.
Figure 1 The aim of future drug treatment in NASH
Abbreviations: CVD, cardiovascular disease; HCC, hepatocellular carcinoma; MetS, Metabolic syndrome; T2DM, type 2 diabetes.

5. EXPERT OPINION

The ideal therapeutic agent(s) in NASH would not only ameliorate liver disease but also treat/prevent multi-morbidity (e.g. T2DM or CVD) associated with NASH. We have described a selection of drugs which have shown promise in early phase clinical trials in NASH, as well as registered trials of combination therapy (Table 2). However, amongst the existing drugs that have been shown to benefit NASH, as mentioned above, pioglitazone has been shown to be effective in treating ~50% of patients with NASH.32

Pioglitazone has become the forgotten, cost effective drug with cardiovascular benefits in the treatment of T2DM.6 Given additional benefits of pioglitazone treatment on the liver in NASH that have been confirmed in meta-analysis32 pioglitazone provides a good bench mark by which other newer drugs should be judged and which should be used in testing combinations of therapies in NASH. In our opinion, any new drugs that are shown to confer benefit on liver disease in NASH, must also test whether these agents are beneficial (or harmful) for T2DM and CVD. For the future, we believe the treatment of NASH will become analogous to the treatment of hypertension as it is highly likely that multiple different classes of drugs targeting different mechanistic pathways will be needed as no single agent is likely to be able to control all aspects of this complex liver disease.
Table 1 Selected phase I/II trials of agents in NAFLD/NASH

<table>
<thead>
<tr>
<th>DRUG</th>
<th>MECHANISM</th>
<th>PHASE</th>
<th>OUTCOME MEASURES</th>
<th>EFFECTS ON LIVER</th>
<th>EFFECTS RELEVANT TO T2DM &amp; CVD</th>
<th>SAFETY</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGM 282</td>
<td>FGF-19 analogue</td>
<td>II</td>
<td>•Histological improvement in NAS (≥2) and no worsening of fibrosis</td>
<td>Decrease</td>
<td>Decrease</td>
<td>•Increased LDL-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>•MRI-PDFF, MRI-cT1, ELF, C4, bile acids, AST, ALT</td>
<td></td>
<td></td>
<td>•GI symptoms most common SEs (diarrhea, nausea, frequent bowel movements, abdominal pain)</td>
</tr>
<tr>
<td>Pegbelfermin</td>
<td>FGF-21 analogue</td>
<td>II</td>
<td>•Safety profile</td>
<td>Decrease</td>
<td>NA</td>
<td>•Suggested decrease in triglycerides</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>•Absolute change in hepatic fat on MRI-PDFF</td>
<td></td>
<td>NA</td>
<td>•Suggested decrease in LDL-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>•GI symptoms most common SEs -7% treatment emergent grade 3 laboratory abnormality</td>
</tr>
<tr>
<td>VK2809*</td>
<td>THR-β agonist</td>
<td>II</td>
<td>•Safety profile</td>
<td>Decrease</td>
<td>NA</td>
<td>•No data – await complete results</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>•Reduction in hepatic fat content on MRI-PDFF</td>
<td></td>
<td>NA</td>
<td>•No SAEs reported</td>
</tr>
<tr>
<td>MGL-3196*</td>
<td>THR-β agonist</td>
<td>II</td>
<td>•Relative reduction in hepatic fat on MRI-PDFF</td>
<td>Decrease</td>
<td>NA</td>
<td>•Decreased LDL-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>•Improved histology; Lipids; ALT, AST.</td>
<td></td>
<td>NA</td>
<td>•3 SAEs which occurred were considered unrelated</td>
</tr>
<tr>
<td>Drug</td>
<td>Mechanism</td>
<td>Stage</td>
<td>Effect 1</td>
<td>Effect 2</td>
<td>Effect 3</td>
<td>Notes/Comments</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------------</td>
<td>-------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>GS-0976 ACC inhibitor II</td>
<td>≥30% relative reduction in hepatic fat on MRI-PDFF</td>
<td>Decrease</td>
<td>NA</td>
<td>No effect on liver stiffness</td>
<td>Increase triglycerides</td>
<td>No SAEs reported attributable to drug</td>
</tr>
<tr>
<td></td>
<td>• MRE</td>
<td></td>
<td></td>
<td></td>
<td>No changes in glucose / insulin / HbA1c</td>
<td>Most common SEs were gastrointestinal and headache</td>
</tr>
<tr>
<td></td>
<td>• ELF, Fibrosure/Fibrotest, cytochrome, acylcarnitine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elafibranor PPAR-α-δ agonist II</td>
<td>Reversal of NASH without worsening of fibrosis</td>
<td>No effect</td>
<td>Decrease</td>
<td>Small decrease or no effect</td>
<td>Decreased LDL-C</td>
<td>Mild reversible increase in serum creatinine</td>
</tr>
<tr>
<td></td>
<td>• Change in NAS; change in steatosis, ballooning, inflammation, fibrosis; liver enzymes; non-invasive serum markers; metabolic profile.</td>
<td></td>
<td></td>
<td></td>
<td>Decreased triglycerides</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Decreased triglycerides</td>
<td></td>
<td></td>
<td></td>
<td>Decreased HbA1c</td>
<td></td>
</tr>
<tr>
<td>Cenicriviroc CCR2/CCR5 antagonist IIb</td>
<td>Improvement of NASH without worsening of fibrosis</td>
<td>No effect</td>
<td>Small decrease or no effect</td>
<td>Modest decrease</td>
<td>No change in weight</td>
<td>Serum rise in amylase without pancreatitis</td>
</tr>
<tr>
<td></td>
<td>• Resolution of NASH without worsening of fibrosis; improvement in fibrosis of ≥1 stage without worsening in NASH.</td>
<td></td>
<td></td>
<td></td>
<td>No change in metabolic profile</td>
<td></td>
</tr>
<tr>
<td>Selonsertib ASK-1 inhibitor II</td>
<td>Improvement in histology</td>
<td>No effect</td>
<td>No effect</td>
<td>Decrease</td>
<td>No change in LDL-C, triglycerides/HbA1c</td>
<td>Most common SEs were headache, nausea and sinusitis</td>
</tr>
<tr>
<td></td>
<td>• Reduction in hepatic fat on MRI-PDFF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ELF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FibroSure/FibroTest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2 Trials of combination therapy in non-alcoholic fatty liver disease (NAFLD)

<table>
<thead>
<tr>
<th>TRIAL IDENTIFIER</th>
<th>PHASE</th>
<th>TARGET</th>
<th>DRUG</th>
<th>PATIENT GROUP</th>
<th>OUTCOME MEASURES</th>
<th>STATUS</th>
<th>n</th>
<th>ESTIMATED COMPLETION DATE</th>
<th>POTENTIAL CHALLENGES / OTHER BENEFITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03646292</td>
<td>IV</td>
<td>•SGLT2i</td>
<td>•Epaglirozin</td>
<td>Patients with both T2DM and NAFLD</td>
<td>•Liver fat change measured by MRI-PDFF</td>
<td>Not yet recruiting</td>
<td>60</td>
<td>Feb 2021</td>
<td>Potential of risk fractures, weight gain and urinary tract infections, improved</td>
</tr>
</tbody>
</table>

Abbreviations: **ACC**, Acetyl-coenzyme A carboxylase; **ASK-1**, Apoptosis signal-regulating kinase 1; **CCR2/CCR5**, CC chemokine receptor types 2 and 5; **CVD**, cardiovascular disease; **ELF**, Enhanced Liver Fibrosis score; **FGF-19**, Fibroblast growth factor 19; **FXR**, Farnesoid X receptor; **LDL-C**, low density lipoprotein cholesterol, **MRE**, magnetic resonance elastography; **MRI-PDFF**, MRI protein density fat fraction; **NAS**, NAFLD Activity Score; **PPAR-α/-δ**, Peroxisome proliferator-activated receptor-α and –δ; **SAE**, serious adverse event; **T2DM**, type 2 diabetes mellitus; **THR-β**, Thyroid hormone receptor-beta; **TLR**, Toll-like receptor

*Presented in abstract. Await complete results.*
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Intervention</th>
<th>Eligibility</th>
<th>Enrollment</th>
<th>Status</th>
<th>Key Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03434613</td>
<td>IV</td>
<td>HMG-CoA reductase inhibitor, Rosuvastatin, Ezetimibe</td>
<td>Patient with both hyperlipidaemia and NAFLD</td>
<td>Recruiting</td>
<td>70, Jan 2020</td>
<td>Muscle aches and previously no mortality benefit in NAFLD treated with lipid lowering drugs</td>
</tr>
<tr>
<td>NCT03776175</td>
<td>IIa</td>
<td>ACCi, DGATi, PF05221304, PF06865571</td>
<td>Patients with NAFLD</td>
<td>Recruiting</td>
<td>98, Oct 2019</td>
<td>Increase plasma ketone bodies, increase hepatic inflammation, improved glucose tolerance</td>
</tr>
<tr>
<td>NCT03517540</td>
<td>II</td>
<td>CCR2/CCR5a, FXRa, Cencriviroc, Tropifexor</td>
<td>NASH with F2/F3 fibrosis on biopsy</td>
<td>Recruiting</td>
<td>200, Sep 2020</td>
<td>Increased LDL-C, pruritus, increase serum amylase</td>
</tr>
<tr>
<td>NCT03449446</td>
<td>II</td>
<td>ASK-1i, ACCi, FXRa, Selonsertib, GS-0976, GS-9674</td>
<td>NASH with F3/F4 fibrosis on biopsy</td>
<td>Active,</td>
<td>395, Oct 2019</td>
<td>Increase plasma ketone bodies, potential treatment of hypertriglyceridaemia, improved glucose tolerance</td>
</tr>
<tr>
<td>NCT03987074</td>
<td>II</td>
<td>GLP-1a, ACCi, FXRa, Semaglutide, GS-0976, GS-9674</td>
<td>NASH with F2/F3 fibrosis: 1) on biopsy, 2) MRI-PDFF / Fibroscan</td>
<td>Not yet recruiting</td>
<td>100, July 2020</td>
<td>Nausea, increase plasma ketone bodies, potential treatment of hypertriglyceridaemia, increase LDL-C, pruritus</td>
</tr>
</tbody>
</table>

Abbreviations: ACCi, Acetyl-coenzyme A carboxylase inhibitor; ASK-1i, Apoptosis signal-regulating kinase 1 inhibitor; CCR2/CCR5a, CC chemokine receptor types 2 and 5 antagonist; DGATi, Diacylglycerol O acyltransferase inhibitor; FXRa, Farnesoid X-activated receptor agonist; GLP-1a, Glucagon-like peptide 1 analogue; HMG-CoA, β-Hydroxy β-methylglutaryl-CoA; LDL-C, low density lipoprotein cholesterol; MRE, magnetic resonance elastography; MRI-PDFF, MRI protein density fat fraction; NASH, non-alcoholic steatohepatitis; NPC1L1i, Niemann-Pick C1-Like 1; SE, side effect; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione.
15. Harrison S, Moussa S, Bashir M, et al. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study. J. Hepatol. 68, S38 (2018).


**REFERENCE ANNOTATIONS (** = of importance, ** = of considerable importance)**

The PIVENS trial demonstrated an improvement in steatosis and steatohepatitis in patients with NASH treated with pioglitazone. However, the PIVENS trial was unable to demonstrate a significant improvement in fibrosis stage in patients with NASH treated with pioglitazone. This meta-analysis by Musso et al demonstrates that thiazolidinediones also improve advanced fibrosis in patients with NASH.


The FLINT trial is of considerable importance because it demonstrated OCA improved NAS in participants without worsening of fibrosis. It also highlighted two of the foremost challenges with OCA, namely pruritus and deterioration in lipid profile.


REGENERATE is of considerable importance because interim analysis suggest OCA may be the first drug eligible to apply for accelerate approval. However, interim analysis did not demonstrate an improvement in NAS in participants treated with OCA. We await future complete peer reviewed reporting.


GS-9674 is of importance because it caused a significant improvement in hepatic steatosis in patients with NASH. There are two planned trials of combination therapy in which GS-9674 will be one of the combination drugs.


This study is of importance because it demonstrates a significant improvement in both steatosis and fibrosis. However, the most common side-effect was diarrhoea, and weight loss was not measured. Therefore, it will be important to assess change in weight in patients in future studies of NGM282, in order to ascertain whether diarrhoea-mediated weight loss is contributing to improvements in liver histology.